Flow cytometry is a primary tool for characterizing immune cell dynamics in high-throughput screening (HTS) assays. However, traditional staining and acquisition procedures demand substantial antibodies, resources, and time. Moreover, HTS assays are often constrained to a minimal set of markers, limiting biological readouts to largely binary outputs (e.g., activated vs. resting) and oversimplifying the complexity of drug responses.
To simplify assays while improving biological insights, we leveraged the imaging capabilities of the Attune CytPix to investigate whether imaging flow cytometry can replace activation and viability markers and detect complex phenotypes based on cellular morphology.
Using brightfield imaging-derived parameters and UMAP dimensionality reduction analysis, we successfully resolved distinct clusters separating human resting Peripheral Blood Mononuclear Cells (PBMC) from activated CD25+CD69+ PBMCs. Additionally, cell debris and morphologically distinct dead cells formed separate populations, suggesting the ability to differentiate modalities of cell death through imaging alone. We then applied an AI-driven Python-based analysis to the CytPix derived images, and successfully reconstructed label-free drug-response curves comparable to those derived via conventional manual gating in standard flow cytometry.
Building on these findings, we are now integrating additional imaging-derived parameters to uncover phenotypes that may not be captured by conventional marker-based approaches, with the goal of enabling richer, label-free HTS readouts at scale.
n/a
Technological Innovations in Immunology (TECH)
Jiangfang Wang, Marjana Begum, Raffaello Cimbro et al.· Journal of Immunology· 0 citations
Targeted protein degradation is a potent strategy against intracellular proteins impervious to traditional drugs. We describe a platform reliant on high-throughput cloning and mRNA-based delivery to quickly screen 100s-1000s of modular biological degraders, which we challenge against the high-turnover c-Myc oncoprotein. We uncover critical principles to drive degrader discovery against any target, free from tagging or prior cell line engineering, with direct applications in research and potentially therapy. We demonstrate the feasibility of targeted protein degradation of c-Myc across in vitro cancer models and in vivo xenograft model, uncovering distinct cellular responses between c-Myc degradation and inhibition.
C. Ascanelli, Samuel Gilberto, C. Batho et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.